

**Real-world Effectiveness and Safety of a Single-Pill Combination of
Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension
and Cardiovascular Risk Factors**

Jaewon Oh¹, Wonho Kim², Gee-Hee Kim³, Hack-Lyoung Kim⁴, Sang-Don Park⁵, Kyung Wan Min⁶, Dongkeun Hyun⁷, Jun Hwa Hong⁸, Soo Lim⁹, Jinho Shin¹⁰, and Investigators

Author Details:

¹Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea.

²Division of Cardiology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea.

³Division of Cardiology, Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Seoul, Korea.

⁴Division of Cardiology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.

⁵Division of Cardiology, Department of Internal Medicine, Inha University Hospital, Korea.

⁶Division of Endocrinology and Metabolism, Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea

⁷Department of Neurosurgery, School of Medicine, Inha University, Incheon, Korea.

⁸Division of Endocrinology, Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea.

⁹Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, Korea

¹⁰Division of Cardiology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea

Correspondence Details:

Jinho Shin

Division of Cardiology, Department of Internal Medicine, Hanyang University College of Medicine, 222-1, Wangsimni-ro, Seongdong-gu, Seoul, Republic of Korea

Phone number: +82 02-2290-8308

Fax number: +82 02-2299-0278

Email: jhs2003@hanyang.ac.kr

SUPPLEMENTARY MATERIALS

Table S1 List of institutions participating in the study

Table S2 List of disease terms coded for high-risk cardiovascular disease

Table S3 Blood pressure reduction at 24 Weeks based on the number of classes of previous antihypertensive drugs

Figure S1 Time-course of blood pressure changes during the study period

Table S1 List of institutions participating in the study

No.	Institution	IRB study number
1	Gyeongsang National University Hospital	D-1806-003-078
2	Gachon University Gil Medical Center	2018AN0190
		GAIRB2018-245
3	The Catholic University of Korea Bucheon Saint Mary's Hospital	HC18OODI0055
4	The Catholic University of Korea Saint Vincent's Hospital	VC18OODI0178
		VC18OODI0128
5	The Catholic University of Korea Yeouido Saint Mary's Hospital	SC18OODI0055
		SC18OODI0064
6	The Catholic University of Korea Eunpyeong Saint Mary's Hospital	PC19MODI0050
7	The Catholic University of Korea Uijeongbu Saint Mary's Hospital	UC18OODI0072
8	Kyung Hee University Hospital at Gangdong	2018-08-040
		2018-06-006
9	Kangbuk Samsung Hospital	2018-09-005
10	Kangwon National University Hospital	2018-07-003
11	Kyung Hee University Medical Center	2018-07-072
12	Korea University Ansan Hospital	2018AS0193
13	Korea University Anam Hospital	2018AN0190
		2018AN0187
14	Kosin University Gospel Hospital	2018-07-036
15	National Health Insurance Service Ilsan hospital	2018-08-003
16	Daegu Veterans Hospital	2019-12 ho
17	Daegu Fatima Hospital	DFH18MRSO363
18	Daejeon Eulji Medical center, Eulji University	2018-07-018
19	Dong-A University Hospital	DAUHIRB-18-162
		DAUHIRB-18-161
		DAUHIRB-18-174
20	SMG-SNU Borame Medical Center	20180723/20-2018-65/082
21	Pusan National University Hospital	GBIRB2018-235
22	Seoul National University Bundang Hospital	B-1808/489-401
23	Saint Carollo Hospital	SCH2018-0112
24	Samsung Changwon Hospital	2018-06-004
25	Soonchunhyang University Hospital Bucheon	2019-08-008
		2018-07-026
26	Soonchunhyang University Hospital Cheonan	2018-07-042
		2018-07-16
27	Ajou University Medical Center	AJIRB-MED-OBS-18-243
28	Gangnam Severance Hospital	3-2018-0234
29	Severance Hospital	4-2018-0592
30	Yongin Severance Hospital	9-2018-0005
31	Wonju Severance Christian Hospital	CR118025
32	Yeungnam University Medical Center	2018-06-028
		2019-02-019
		2018-06-027

33	Ulsan University Hospital	2018-08-015
34	Nowon Eulji Medical Center, Eulji University	2018-06-009
35	Eulji Medical Center, Eulji University	2018-06-014
		2019-06-024
		2019-06-025
36	Inje University Sanggye Paik Hospital	2018-08-006
37	Inje University Haeundae Paik Hospital	2018-06-023
38	Inha University Hospital	2018-06-024
		2018-06-016
39	Chonnam National University Hospital	CNUH-2019-187
40	Chosun University Hospital	2018-06-002
		2019-08-014
41	Chung-Ang University Hospital	1860-002-327
42	Kyungpook National University Chilgok Hospital	2018-07-002
43	Hallym University Kangnam Sacred Heart Hospital	2019-08-007
44	Hallym University Sacred Heart Hospital	2018-06-023
45	Hanyang University Guri Hospital	2018-06-016
46	Hanyang University Medical Center	2018-07-063
47	Chonnam National University Hwasun Hospital	CNUHH-2018-114

Abbreviation: IRB, institutional review board

Table S2 List of disease terms coded for high-risk cardiovascular disease

Preferred term
Acute myocardial infarction
Aneurysm
Aneurysm arteriovenous
Aneurysm ruptured
Angina pectoris
Angina unstable
Angiopathy
Aortic aneurysm
Aortic arteriosclerosis
Aortic dissection
Arterial occlusive disease
Arteriosclerosis
Basal ganglia hemorrhage
Basal ganglia infarction
Basilar artery stenosis
Brain stem hemorrhage
Brain stem infarction
Cardiac failure
Cardiac failure chronic
Cardiac failure congestive
Cardiac hypertrophy
Cardiomegaly
Carotid arteriosclerosis
Carotid artery aneurysm
Carotid artery occlusion
Carotid artery stenosis
Cerebellar hemorrhage
Cerebellar infarction
Cerebral arteriosclerosis
Cerebral artery occlusion
Cerebral artery stenosis
Cerebral hematoma
Cerebral hemorrhage
Cerebral infarction
Cerebral ischemia
Cerebral small vessel ischemic disease
Cerebrovascular accident
Cerebrovascular disorder
Cerebrovascular insufficiency
Congestive cardiomyopathy
Cor pulmonale
Coronary artery disease
Coronary artery occlusion
Coronary artery stenosis
Diabetic vascular disorder
Embolic cerebral infarction
Epidural hemorrhage
Hemorrhage intracranial
Hemorrhagic cerebral infarction

Hypertensive heart disease
Iliac artery occlusion
Infarction
Intermittent claudication
Intracranial aneurysm
Intracranial hematoma
Intraventricular hemorrhage
Ischemic cardiomyopathy
Ischemic stroke
Lacunar infarction
Left ventricular dysfunction
Left ventricular failure
Left ventricular hypertrophy
Microvascular coronary artery disease
Myocardial bridging
Myocardial infarction
Myocardial ischemia
Peripheral arterial occlusive disease
Peripheral artery thrombosis
Peripheral vascular disorder
Precerebral artery occlusion
Prinzmetal angina
Ruptured cerebral aneurysm
Subarachnoid hemorrhage
Subarachnoid hemorrhage neonatal
Subdural hemorrhage
Systolic dysfunction
Thalamic infarction
Thalamus hemorrhage
Thrombophlebitis superficial
Thrombotic cerebral infarction
Transient ischemic attack
Traumatic intracranial hemorrhage
Vertebral artery aneurysm
Vertebral artery dissection
Vertebral artery stenosis
Vertebrobasilar insufficiency

*The Medical Dictionary for Regulatory Activities version 21.0 was used to code the terms for high-risk cardiovascular diseases

Table S3 Blood pressure reduction at 24 Weeks based on the number of classes of previous antihypertensive drugs

The number of classes of previous antihypertensive drugs	Number of patients	Systolic blood pressure/Diastolic blood pressure, mmHg			P-value
		Baseline	Week 24	Change from baseline at week 24	
0	303	155.27 (19.52)/ 90.70(15.33)	126.92 (16.69)/ 74.71(12.08)	-28.34 (22.63)/ -15.99(15.46)	<0.0001* / <0.0001*
1	426	151.5 (17.3)/ 86.6 (12.9)	126.5 (15.0)/ 73.7 (11.0)	-25.0 (19.8)/ -13.0 (12.5)	<0.0001 [†] / <0.0001 [†]
2	1,080	146.0 (16.5)/ 83.5 (12.4)	129.9 (15.2)/ 75.2 (11.3)	-16.2 (19.1)/ -8.4 (12.5)	<0.0001 [†] / <0.0001 [†]
3	459	140.6 (16.7)/ 79.5 (11.8)	130.2 (15.6)/ 74.7 (10.9)	-10.4 (19.5)/ -4.7 (12.5)	<0.0001 [†] / <0.0001 [†]
4 or more	92	139.2 (17.3)/ 76.8 (11.9)	132.0 (16.4)/ 72.7 (12.5)	-7.2 (20.5)/ -4.1 (14.7)	0.0011* / 0.0089*

*Statistical significance was tested using paired t test

[†]Statistical significance was tested using Wilcoxon's signed rank test




Figure S1. Time-course of blood pressure changes during the study period. (a) Time course of changes in SBP and DBP for the total dose of O/A/H. (b) Time course of changes in SBP and DBP for each dose of O/A/H.

Abbreviation: BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure

*O/A/H represents the single-pill combination therapy of olmesartan, amlodipine, and hydrochlorothiazide.

†Mean SBP and DBP at baseline and subsequent visits are presented as standard deviations.